Dr. Neal on Ongoing Trials of Immunotherapy for Lung Cancer

Joel Neal, MD, PhD
Published: Friday, Feb 10, 2017



Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses ongoing trials in immunotherapy for patients with lung cancer.

EGFR inhibitors looking to overcome acquired resistance is a trial that Neal says he is excited to see the results of. At Stanford, there are always patients with EGFR-mutant lung cancer who are looking for new lines of therapy after they have failed on other treatments.

Beyond PD-1/PD-L1 immunotherapy, researchers are looking towards T-cell transgenic therapy trials. Stanford is opening new cellular therapy trials looking to reopen patient’s own T cells to try and combat the cancer in a way that they might not have otherwise.
 


Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses ongoing trials in immunotherapy for patients with lung cancer.

EGFR inhibitors looking to overcome acquired resistance is a trial that Neal says he is excited to see the results of. At Stanford, there are always patients with EGFR-mutant lung cancer who are looking for new lines of therapy after they have failed on other treatments.

Beyond PD-1/PD-L1 immunotherapy, researchers are looking towards T-cell transgenic therapy trials. Stanford is opening new cellular therapy trials looking to reopen patient’s own T cells to try and combat the cancer in a way that they might not have otherwise.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x